Recently, HIF1A has been shown to induce VTCN1 in multiple myeloma, cervical, and breast cancer cell lines (Jeon et al, 2015), which may be a part of the mechanism by which VTCN1 is regulated in IMA. Here, HIF1A is linked to plasma cell myeloma.